Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis-Reference-Cited by-同舟云学术

Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis

Published:2023-07 Issue: Volume:188 Page:64-79
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Boutros Andrea,Tanda Enrica Teresa,Croce Elena,Catalano Fabio,Ceppi Marcello,Bruzzone Marco,Cecchi Federica,Arecco Luca,Fraguglia Matteo,Pronzato Paolo,Genova Carlo,Del Mastro Lucia,Lambertini Matteo,Spagnolo Francesco

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference62 articles.

1. Systematic review of medical treatment in melanoma: current status and future prospects;Garbe;Oncologist,2011

2. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067;Hodi;J Clin Oncol,2022

3. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019

4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

5. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical, dermatoscopic, histological and molecular predictive factors of distant melanoma metastasis: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-10

2. VISTA: A promising target for overcoming immune evasion in gynecologic cancers;International Immunopharmacology;2024-09

3. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data;Journal of Clinical Oncology;2024-08-13

4. Characteristics and management of sclerosing skin diseases during immune checkpoint inhibitor therapy: An evidence-based review;Journal of the American Academy of Dermatology;2024-07

5. Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment;2024-06-17